,4 Specifically, CAR-T cells targeting CD19 or B cell maturation antigen (BCMA) in treating B cell lymphoma, leukemia, and multiple myeloma have achieved unprecedented response rates.5 The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.